(53 days)
Not Found
No
The description focuses on a microdilution technique and automated monitoring of bacterial growth, with no mention of AI or ML algorithms for analysis or interpretation.
No
This device is an in vitro diagnostic (IVD) test designed to identify the susceptibility of microorganisms to antimicrobial agents. It is a laboratory aid for determining the appropriate treatment, not a device that directly treats a condition or delivers a therapy.
Yes
The device is designed for antimicrobial susceptibility testing of microorganisms, providing a laboratory aid in determining in vitro susceptibility to antimicrobial agents. This information is used to guide treatment decisions for bacterial infections, which is a diagnostic purpose.
No
The device description explicitly details a physical AST card with wells containing premeasured antibiotic and culture media, which is a hardware component. The system also involves automated or manual filling, sealing, and incubation, indicating a hardware-dependent process.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the device is "designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." The phrase "in vitro susceptibility" is a key indicator of an IVD.
- Device Description: The description details a test performed on a sample (microorganisms) outside of the body ("in vitro") to provide information about the susceptibility of those microorganisms to antimicrobial agents.
- Clinical Laboratories: The "Intended User / Care Setting" is listed as "clinical laboratories," which are the typical settings where IVDs are used.
- Performance Studies: The document describes performance studies comparing the device to a reference method (CLSI broth microdilution), which is standard practice for validating IVDs.
- Predicate Device: A predicate device (K190616; VITEK® 2 AST-Gram Positive Dalbavancin) is listed, which is another IVD, further supporting the classification of this device as an IVD.
All of these points align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
VITEK® 2 AST-Gram Positive Delafloxacin is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Positive Delafloxacin is a quantitative test. Delafloxacin has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.
Active in vitro and in clinical infections: Acute Bacterial Skin and Skin Structure Infections (ABSSSI):
Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates) Streptococcus agalactiae Enterococcus faecalis
Community-Acquired Bacterial Pneumonia (CABP):
Staphylococcus aureus (methicillin-susceptible isolates only)
The VITEK® 2 Gram-positive Susceptibility Card is intended for use with the VITEK® 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of Staphylococcus spp., Enterococcus spp., and S. agalactiae to antimicrobial agents when used as instructed.
Product codes (comma separated list FDA assigned to the subject device)
LON
Device Description
The principle of the VITEK® 2 AST cards is based on the microdilution minimum inhibitory concentration (MIC) technique reported by MacLowry and Marsh() and Gerlach(0). The VITEK @ 2 AST card is essentially a miniaturized, abbreviated and automated version of the doubling dilution technique(3).
Each VITEK® 2 AST card contains 64 wells. A control well which only contains microbiological culture media is resident on all cards. The remaining wells contain premeasured portions of a specific antibiotic combined with culture media. The isolate to be tested is diluted to a standardized concentration with 0.45 – 0.5% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling, sealing and loading operation. The VITEK® 2 Systems monitor the growth of each well in the card over a defined period of time. At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Laboratory aid / clinical laboratories
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The Premarket Notification (510[k]) presents data in support of VITEK® 2 AST-Gram Positive Delafloxacin. An external evaluation was conducted with contemporary and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 AST-Gram Positive Delafloxacin by comparing its performance with the CLSI broth microdilution reference method incubated at 16-20 hrs for Staphylococci and Enterococci and 20-24 hrs for Streptococci. The data is representative of performance on both the VITEK® 2 Compact instrument platforms.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
External evaluation was conducted.
The VITEK® 2 AST-Gram Positive Delafloxacin demonstrated acceptable performance as presented in Table 2.
ABSSSI (Overall) Essential Agreement (EA) = 96.6% (737/763), Category Agreement (CA) = 94.0% (717/763)
ABSSSI (E. faecalis) EA = 95.0% (342/360), CA = 94.4% (340/360)
ABSSSI (MSSA+MRSA) EA = 98.2% (320/326), CA = 92.0% (300/326)
ABSSSI (S. agalactiae) EA = 97.4% (75/77), CA = 100% (77/77)
CABP (MSSA) EA = 99.4% (169/170), CA = 97.1% (165/170)
% Reproducibility for Delafloxacin ABSSSI (MSSA+MRSA) = 100.0%.
NOTE: VITEK® 2 AST-Gram Positive Delafloxacin MIC values tended to be in exact agreement or at least one doubling dilution higher when testing Staphylococcus aureus compared to the CLSI reference broth microdilution method.
NOTE: When evaluating performance of the challenge isolates on the manual dilution option for the VITEK® 2 and VITEK® 2 Compact, testing with MRSA isolates yielded an EA of 85% (17/20) and an CA of 80% (16/20). For challenge isolates on the auto dilution option for the VITEK® 2, testing with MRSA isolates yielded an EA of 85% (17/20) and an CA of 85% (17/20). All categorical errors were considered minor.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement (EA), Category Agreement (CA), Very Major Errors (VME), Major Errors (ME), Minor Errors (mE), Reproducibility.
For Delafloxacin:
ABSSSI (Overall): %EA 96.6% (737/763), %CA 94.0% (717/763), VME (2/136) 1.5%, ME (3/594) 0.5%, mE (41/763) 5.4%
ABSSSI (E. faecalis): %EA 95.0% (342/360), %CA 94.4% (340/360), VME (2/98) 2.0%, ME (1/252) 0.4%, mE (17/360) 4.7%
ABSSSI (MSSA+MRSA): %EA 98.2% (320/326), %CA 92.0% (300/326), VME (0/36) 0.0%, ME (2/267) 0.7%, mE (24/326) 7.4%, % Reproducibility 100.0
ABSSSI (S. agalactiae): %EA 97.4% (75/77), %CA 100% (77/77), VME (0/2) 0.0%, ME (0/75) 0.0%, mE (0/77) 0.0%
CABP (MSSA): %EA 99.4% (169/170), %CA 97.1% (165/170), VME (0/7) 0.0%, ME (0/155) 0.0%, mE (5/170) 2.9%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym and name on the right. The FDA part of the logo is in blue, with the acronym "FDA" in a square and the words "U.S. FOOD & DRUG ADMINISTRATION" next to it.
April 28, 2020
bioMerieux, Inc Cherece Jones Staff Regulatory Affairs Specialist 595 Anglum Rd. Hazelwood, Missouri 63042
Re: K200590
Trade/Device Name: VITEK 2 AST-Gram Positive Delafloxacin (≤0.015 - ≥1 µg/mL) Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System Regulatory Class: Class II Product Code: LON, LTT, LTW Dated: March 4, 2020 Received: March 6, 2020
Dear Cherece Jones:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR
1
- for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-
542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Ribhi Shawar. Ph.D. (ABMM) Chief General Bacteriology and Antimicrobial Susceptibility Branch Division of Microbiology Devices OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/0 description: The image shows the logo for bioMérieux. The logo consists of a circle that is split into two halves. The top half of the circle is blue, and the bottom half is a gradient of yellow and green. The word "BIOMÉRIEUX" is written in white letters across the middle of the circle.
510(k) SUMMARY
C.
VITEK® 2 AST-Gram Positive Delafloxacin (≤0.015-≥1 µg/mL)
A. 510(k) Submission Information:
| Submitter's Name: | bioMérieux, Inc. |
|---|---|
| Address: | 595 Anglum Road |
| Hazelwood, MO 63042 | |
| Contact Person: | Cherece L. Jones |
| Staff Regulatory Affairs Specialist | |
| Phone Number: | 314-731-8684 |
| Fax Number: | 314-731-8689 |
| Date of Preparation: | March 4, 2020 |
| B. Device Name: | |
| Formal/Trade Name: | VITEK® 2 AST-Gram Positive Delafloxacin (≤0.015 - ≥1 µg/mL) |
| Classification Name: | 21 CFR 866.1645 |
| Fully Automated Short-Term Incubation Cycle | |
| Antimicrobial Susceptibility System | |
| Product Code: LON | |
| Common Name: | VITEK® 2 AST-GP Delafloxacin (≤0.015 - ≥1 µg/mL) |
| C. Predicate Device: | VITEK® 2 AST-Gram Positive Dalbavancin (≤0.015 - |
| ≥1 µg/mL) (K190616) | |
| D. Device Description: |
The principle of the VITEK® 2 AST cards is based on the microdilution minimum inhibitory concentration (MIC) technique reported by MacLowry and Marsh() and Gerlach(0). The VITEK @ 2 AST card is essentially a miniaturized, abbreviated and automated version of the doubling dilution technique(3).
Each VITEK® 2 AST card contains 64 wells. A control well which only contains microbiological culture media is resident on all cards. The remaining wells contain premeasured portions of a
3
Image /page/3/Picture/0 description: The image shows the logo for bioMérieux, a French multinational biotechnology company. The logo consists of a blue circle at the top and a yellow-green gradient at the bottom. The company name, "BIOMÉRIEUX", is written in white letters across the blue circle.
specific antibiotic combined with culture media. The isolate to be tested is diluted to a standardized concentration with 0.45 – 0.5% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling, sealing and loading operation. The VITEK® 2 Systems monitor the growth of each well in the card over a defined period of time. At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
E. Substantial Equivalence Information:
The similarities and differences of the VITEK® 2 AST-GP Delafloxacin (≤0.015-≥1 µg/mL) when compared to the predicate device, VITEK® 2 AST-Gram Positive Dalbavancin (≤0.015 ->1 ug/mL), are described in the Table 1 below.
| Item | Device:
VITEK® 2 AST-GP Delafloxacin
(≤0.015 - ≥1 µg/mL) | Predicate:
VITEK® 2 AST-Gram Positive
Dalbavancin (≤0.015 - ≥1 µg/mL)
(K190616) |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Similarities | |
| Intended Use | VITEK® 2 AST-Gram Positive
Delafloxacin is designed for
antimicrobial susceptibility testing of
Gram positive microorganisms and is
intended for use with the VITEK® 2
and VITEK® 2 Compact Systems as
a laboratory aid in the determination
of in vitro susceptibility to
antimicrobial agents. VITEK® 2
AST-Gram Positive Delafloxacin is a
quantitative test. Delafloxacin has
been shown to be active against most
strains of the microorganisms listed
below, according to the FDA label
for this antimicrobial.
Active in vitro and in clinical
infections:
Acute Bacterial Skin and Skin
Structure Infections (ABSSSI):
Staphylococcus aureus (including
methicillin-resistant and methicillin-
susceptible isolates)
Streptococcus agalactiae
Enterococcus faecalis
Community-Acquired Bacterial | VITEK® 2 AST-Gram Positive
Dalbavancin is designed for
antimicrobial susceptibility testing of
Gram positive microorganisms and is
intended for use with the VITEK® 2
and VITEK® 2 Compact Systems as a
laboratory aid in the determination of
in vitro susceptibility to antimicrobial
agents. VITEK® 2 AST-Gram Positive
Dalbavancin is a quantitative test.
Dalbavancin has been shown to be
active against most strains of the
microorganisms listed below,
according to the FDA label for this
antimicrobial.
Active both in vitro and in clinical
infections
Staphylococcus aureus (including
methicillin-resistant isolates)
Enterococcus faecalis (vancomycin-
susceptible isolates only)
Streptococcus agalactiae
The VITEK® 2 Gram-positive
Susceptibility Card is intended for use
with the VITEK® 2 Systems in clinical |
Table 1: Substantial Equivalence
4
Image /page/4/Picture/0 description: The image shows the logo for bioMérieux. The logo is a circle that is split into two halves. The top half is blue and contains the word "BIOMÉRIEUX" in white sans-serif font. The bottom half is a gradient of yellow and green.
| Item | Device:
VITEK® 2 AST-GP Delafloxacin
(≤0.015 - ≥1 µg/mL) | Predicate:
VITEK® 2 AST-Gram Positive
Dalbavancin (≤0.015 - ≥1 µg/mL)
(K190616) |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Similarities | | |
| | Pneumonia (CABP):
Staphylococcus aureus (methicillin-
susceptible isolates only)
The VITEK® 2 Gram-positive
Susceptibility Card is intended for
use with the VITEK® 2 Systems in
clinical laboratories as an in vitro test
to determine the susceptibility of
Staphylococcus spp., Enterococcus
spp., and S. agalactiae to
antimicrobial agents when used as
instructed. | laboratories as an in vitro test to
determine the susceptibility of
Staphylococcus spp., Enterococcus
spp., and S. agalactiae to
antimicrobial agents when used as
instructed. |
| Test Methodology | Automated quantitative antimicrobial
susceptibility test for use with the
VITEK® 2 and VITEK® 2 Compact
Systems to determine the in vitro
susceptibility of microorganisms | Same |
| Inoculum | Saline suspension of organism | Same |
| Test Card | Gram Positive (AST-GP)
Susceptibility Card | Same |
| Analysis Algorithms | Growth Pattern Analysis | Same |
| Instrument | VITEK® 2 and VITEK® 2 Compact
Systems | Same |
| Differences | | |
| Antimicrobial Agent | Delafloxacin | Dalbavancin |
| Concentrations | 0.008, 0.03, 0.06, 0.25 | 0.0625, 0.125, 0.25, 0.5 |
F. Indications for Use:
VITEK® 2 AST-Gram Positive Delafloxacin is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Positive Delafloxacin is a quantitative test. Delafloxacin has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.
Active in vitro and in clinical infections: Acute Bacterial Skin and Skin Structure Infections (ABSSSI):
5
Image /page/5/Picture/0 description: The image shows the logo for bioMérieux. The logo is a circle with a blue top half and a green bottom half. The word "BIOMÉRIEUX" is written in white letters in the blue portion of the circle. The green portion of the circle is a gradient, with the top being a lighter shade of green and the bottom being a darker shade of green.
Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates) Streptococcus agalactiae Enterococcus faecalis
Community-Acquired Bacterial Pneumonia (CABP):
Staphylococcus aureus (methicillin-susceptible isolates only)
The VITEK® 2 Gram-positive Susceptibility Card is intended for use with the VITEK® 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of Staphylococcus spp., Enterococcus spp., and S. agalactiae to antimicrobial agents when used as instructed.
G. Performance Overview and Conclusion:
VITEK® 2 AST-Gram Positive Delafloxacin demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA (Issued August 28, 2009).
The Premarket Notification (510[k]) presents data in support of VITEK® 2 AST-Gram Positive Delafloxacin. An external evaluation was conducted with contemporary and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 AST-Gram Positive Delafloxacin by comparing its performance with the CLSI broth microdilution reference method incubated at 16-20 hrs for Staphylococci and Enterococci and 20-24 hrs for Streptococci. The data is representative of performance on both the VITEK® 2 Compact instrument platforms.
The VITEK® 2 AST-Gram Positive Delafloxacin demonstrated acceptable performance as presented in Table 2 below:
6
Image /page/6/Picture/0 description: The image shows the logo for bioMérieux. The logo is a circle with a blue top half and a green bottom half. The word "BIOMÉRIEUX" is written in white letters across the center of the blue half of the circle.
| Antimicrobial | Comment | Essential Agreement Category | Category Agreement | % Reproducibility | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| %EA | VME | ME | mE | %CA | VME | ME | mE | |||
| #, E | ||||||||||
| ABSSSI | ||||||||||
| (Overall) | (737/763) | |||||||||
| 96.6% | N/A | N/A | N/A | (717/763) | ||||||
| 94.0% | (2/136) | |||||||||
| 1.5% | (3/594) | |||||||||
| 0.5% | (41/763) | |||||||||
| 5.4% | ||||||||||
| #, E | ||||||||||
| ABSSSI (E. | ||||||||||
| faecalis) | (342/360) | |||||||||
| 95.0% | N/A | N/A | N/A | (340/360) | ||||||
| 94.4% | (2/98) | |||||||||
| 2.0% | (1/252) | |||||||||
| 0.4% | (17/360) | |||||||||
| 4.7% | ||||||||||
| Delafloxacin | #, E | |||||||||
| ABSSSI | ||||||||||
| (MSSA+MRS | ||||||||||
| A) | (320/326) | |||||||||
| 98.2% | N/A | N/A | N/A | (300/326) | ||||||
| 92.0% | (0/36) | |||||||||
| 0.0% | (2/267) | |||||||||
| 0.7% | (24/326) | |||||||||
| 7.4% | 100.0 | |||||||||
| #, E | ||||||||||
| ABSSSI | ||||||||||
| (S.agalactiae) | (75/77) | |||||||||
| 97.4% | N/A | N/A | N/A | (77/77) | ||||||
| 100% | (0/2) | |||||||||
| 0.0% | (0/75) | |||||||||
| 0.0% | (0/77) | |||||||||
| 0.0% | ||||||||||
| #, E | ||||||||||
| CABP | ||||||||||
| (MSSA) | (169/170) | |||||||||
| 99.4% | N/A | N/A | N/A | (165/170) | ||||||
| 97.1% | (0/7) | |||||||||
| 0.0% | (0/155) | |||||||||
| 0.0% | (5/170) | |||||||||
| 2.9% | ||||||||||
| NOTE: VITEK® 2 AST-Gram Positive Delafloxacin MIC values tended to be in exact agreement or at least one doubling dilution higher | ||||||||||
| when testing Staphylococcus aureus compared to the CLSI reference broth microdilution method. | ||||||||||
| NOTE: When evaluating performance of the challenge isolates on the manual dilution option for the VITEK® 2 and VITEK® 2 Compact, | ||||||||||
| testing with MRSA isolates yielded an EA of 85% (17/20) and an CA of 80% (16/20). For challenge isolates on the auto dilution option for | ||||||||||
| the VITEK® 2, testing with MRSA isolates yielded an EA of 85% (17/20) and an CA of 85% (17/20). All categorical errors were | ||||||||||
| considered minor |
Toblo 21 VITEY® 2 AST Crom Pocitive Dolofloxacin Parfarmon
Key: #= US Food and Drug Administration 510(k) cleared
E = External performance data
Quality Control demonstrated acceptable results.
H. References:
-
- MacLowry, J.D. and Marsh, H.H., Semi-automatic Microtechnique for Serial Dilution Antibiotic Sensitivity Testing in the Clinical laboratory, Journal of Laboratory Clinical Medicine, 72:685-687, 1968.
-
- Gerlach, E.H., Microdilution 1: A Comparative Study, p. 63-76. Current Techniques for Antibiotic Susceptibility Testing. A. Balows (ed.), Charles C. Thomas, Springfield, IL, 1974.
7
Image /page/7/Picture/0 description: The image shows the logo for bioMérieux. The logo is a circle with the top half being dark blue and the bottom half being a gradient from yellow to green. The word "BIOMÉRIEUX" is written in white, sans-serif font in the center of the blue portion of the circle.
-
- Barry, A.L., The Antimicrobic Susceptibility Test, Principles and Practices, Lea and Febiger, Philadelphia, PA, 1976.